|
WUMC-Cancer and Leukemia Group B
|
5U10CA077440-11
|
$334,932
|
$150,719
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Vitamin D and Ovarian Cancer Prevention and Treatment
|
5R01CA111334-04
|
$244,382
|
$12,219
|
BAI, WENLONG
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$58,923
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VCU Minority-Based CCOP
|
5U10CA052784-18
|
$577,110
|
$92,338
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-33S1
|
$74,165
|
$742
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-33
|
$6,658,653
|
$66,587
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-24
|
$1,880,470
|
$225,656
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
University of Texas SPORE in Lung Cancer
|
2P50CA070907-11
|
$2,300,000
|
$46,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-09
|
$2,180,816
|
$436,163
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Rochester Cancer Center CCOP Research Base
|
3U10CA037420-24S1
|
$46,973
|
$10,804
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-24
|
$1,338,526
|
$307,861
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Iowa CALGB Institutional Grant
|
5U10CA047642-21
|
$110,413
|
$49,686
|
VAENA, DANIEL
|
UNIVERSITY OF IOWA
|
|
University of Colorado Southwest Oncology Group
|
3U10CA042777-21S1
|
$420,576
|
$96,732
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-21
|
$82,101
|
$18,883
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S4
|
$2,630,152
|
$26,302
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S5
|
$61,584
|
$616
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Understanding resistance to HER family tyrosine kinase inhibitors
|
5R01CA122216-02
|
$327,722
|
$81,931
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
U10 Ful Member Application Affiliated with SWOG
|
5U10CA105409-05
|
$71,573
|
$16,462
|
LIPPMAN, SCOTT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Treatment of Malignant Gliomas with 2-5A-anti-hTR
|
5R01CA108558-05
|
$293,510
|
$146,755
|
BOGLER, OLIVER
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Treatment of lung cancer
|
5K24CA100014-05
|
$124,132
|
$62,066
|
LAU, DERICK
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-12
|
$203,525
|
$101,763
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-25
|
$721,858
|
$86,623
|
SCHAEFER, PAUL
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
The Siteman Center of Cancer Nanotechnology Excellence *
|
5U54CA119342-04
|
$3,284,302
|
$985,291
|
WICKLINE, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
The Role of NF-kappaB in Chemotherapy Resistance
|
5R01CA098871-04
|
$340,162
|
$34,016
|
CUSACK, JAMES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
The role of JNK in Mammary tumor development
|
5R01CA100238-06
|
$278,349
|
$27,835
|
VAN DEN BERG, CARLA
|
UNIVERSITY OF TEXAS AUSTIN
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S1
|
$91,948
|
$919
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S2
|
$49,383
|
$494
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-15S3
|
$83,152
|
$832
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-15
|
$5,084,061
|
$50,841
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
|
5K23CA121994-03
|
$136,080
|
$34,020
|
Gonzalez-Angulo, Ana
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The MIT-Harvard Center of Cancer Nanotechnology Excelle*
|
5U54CA119349-04
|
$4,010,088
|
$802,018
|
LANGER, ROBERT
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
The Gulf Coast MBCCOP
|
7U10CA128536-02
|
$539,869
|
$75,582
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
Z01 SC 010098
|
$298,418
|
$14,921
|
Dahut, William
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology*
|
5U10CA114671-02
|
$554,189
|
$77,586
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
7R01CA077091-05
|
$338,540
|
$338,540
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Taxane Resistance in Breast and Ovarian Cancer Cells
|
5R01CA114037-02
|
$297,730
|
$297,730
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
Targeting Vessels in Tumors
|
5P01CA104898-04
|
$2,637,795
|
$52,756
|
SCHNITZER, JAN
|
SIDNEY KIMMEL CANCER CENTER
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-02
|
$278,768
|
$139,384
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells
|
1R01CA138197-01
|
$475,325
|
$47,533
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting mTOR for Cancer Therapy
|
5R01CA112199-04
|
$233,253
|
$58,313
|
MERIC-BERNSTAM, FUNDA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
|
5P01CA116676-03
|
$1,490,578
|
$327,927
|
KHURI, FADLO
|
EMORY UNIVERSITY
|
|
Targeting Cell Cycle Machinery For Cancer Therapy
|
5R01CA109820-05
|
$292,538
|
$146,269
|
Reddy, E
|
TEMPLE UNIVERSITY
|
|
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development
|
1R01CA134767-01
|
$340,300
|
$85,075
|
NELKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
|
Taccalonolides: Mechanisms of Action and Cellular Resistance
|
5R01CA121138-03
|
$289,061
|
$72,265
|
Mooberry, Susan
|
SOUTHWEST FOUNDATION FOR BIOMEDICAL RES
|
|
Syracuse Hematology-Oncology CCOP
|
5U10CA045389-22
|
$575,881
|
$92,141
|
KIRSHNER, JEFFREY
|
HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY
|
|
Synthetic Studies Related to Cancer Research/Treatment
|
5R37CA031845-28
|
$437,130
|
$109,283
|
WENDER, PAUL
|
STANFORD UNIVERSITY
|
|
Synthesis of Antitumor Natural Products
|
5R01CA022215-31
|
$472,682
|
$141,805
|
KISHI, YOSHITO
|
HARVARD UNIVERSITY
|
|
SWOG Institutional Grant
|
5U10CA073590-12
|
$1
|
$0
|
SONDAK, VERNON
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Survivin expression and cancer cell drug resistance
|
5R01CA109481-05
|
$236,953
|
$236,953
|
Li, Fengzhi
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Surface-modified pharmaceutical nanocarriers for subcellular targeting
|
1R01CA128486-01A2
|
$309,797
|
$154,899
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
Total relevant funding to Taxol for this search: $63,184,616
|